The viscosupplementation market size has grown rapidly in recent years. It will grow from $4.1 billion in 2024 to $4.55 billion in 2025 at a compound annual growth rate (CAGR) of 10.8%. The growth in the historic period can be attributed to aging population, rising obesity rates, enhanced insurance coverage, growing awareness, patient preference, increased osteoarthritis cases.
The viscosupplementation market size is expected to see rapid growth in the next few years. It will grow to $6.81 billion in 2029 at a compound annual growth rate (CAGR) of 10.6%. The growth in the forecast period can be attributed to regulatory support, alternative payment models, increased healthcare expenditure, research and development, expansion of indications. Major trends in the forecast period include outcome-based payment models, patient education initiatives, biomarker development, gene therapy research, value-based care models.
The increasing prevalence of osteoarthritis is poised to be a significant driver for the viscosupplementation market in the foreseeable future. Osteoarthritis, a degenerative joint disease and a common form of arthritis, manifests in the breakdown of joints, particularly in areas such as the hips, knees, and hands. Viscosupplementation treatment, involving the direct injection of hyaluronic acid into bone joints, serves to alleviate pain and enhance smooth bone movement. According to the Centers for Disease Control and Prevention (CDC), an American public health service organization, a projected 78.4 million adults aged 18 years and older in the USA are expected to be afflicted by arthritis by the year 2040. This underscores the pivotal role of the rising prevalence of osteoarthritis in propelling the growth trajectory of the viscosupplementation market.
Anticipated growth in healthcare expenditure is set to foster the expansion of the viscosupplementation market in the coming years. Healthcare expenditure, denoting the total spending on healthcare costs, encompasses the financial outlay on healthcare-related goods and services within a specific healthcare system or economy. The surge in healthcare expenditure plays a pivotal role in advancing the broader adoption and increased accessibility of viscosupplementation. This support extends to various aspects, including research, training, infrastructure development, and coverage by healthcare plans, ultimately benefiting individuals grappling with joint-related issues. As of November 2022, the Canadian Institute for Health Information, a U.S.-based not-for-profit organization, reported a notable increase in healthcare expenditure to 0.8%, reaching $331 billion in 2022, compared to 7.6% in 2021. Consequently, the upward trajectory of healthcare expenditure emerges as a driving force behind the growth of the viscosupplementation market.
The viscosupplementation market is witnessing a surge in popularity driven by advancements in technology. Companies within this market are strategically embracing new technologies to maintain their competitive edge. In August 2021, Seikagaku Corporation, a prominent Japanese pharmaceutical firm, unveiled HyLink, an innovative viscosupplement designed for intra-articular single injection to address knee osteoarthritis. HyLink incorporates cross-linking technology, a method used to create a long-lasting cross-linked hyaluronate hydrogel that effectively persists in the joint cavity, establishing it as a durable treatment solution. This move reflects Seikagaku Corporation's commitment to staying at the forefront of technological developments within the viscosupplementation sector.
Leading companies in the viscosupplementation market are actively pursuing innovation to secure a competitive advantage. A notable example is Nuvo Pharmaceuticals Inc., a Canada-based pharmaceutical company, which, in January 2021, introduced NeoVisc+ 2 mL and NeoVisc ONE 4 mL in the Canadian market. These products are hyaluronic acid (HA) viscosupplements specifically designed to address pain relief and enhance joint functionality in patients with degenerative or mechanical arthropathy of the knee, commonly associated with osteoarthritis. The launch of NeoVisc+ 2 mL and NeoVisc ONE 4 mL underscores Nuvo Pharmaceuticals Inc.'s dedication to delivering cutting-edge treatment options for knee pain and osteoarthritis, contributing to the overall growth of the viscosupplementation market in Canada.
In December 2021, Avanos Medical Inc., a medical technology company based in the United States, successfully completed the acquisition of OrthogenRx Inc. for a total transaction value of $160 million. This strategic move significantly expanded, diversified, and enhanced Avanos Medical Inc.'s chronic pain product portfolio, specifically by incorporating treatment options for individuals with knee osteoarthritis. The acquisition was strategically aligned with the company's objective to fortify its partnerships with healthcare providers on a global scale, particularly in the realm of musculoskeletal pain treatment. OrthogenRx Inc., a U.S.-based medical device company with expertise in viscosupplementation therapies for knee osteoarthritis, played a pivotal role in reinforcing Avanos Medical Inc.'s position in this therapeutic space.
Major companies operating in the viscosupplementation market include Seikagaku Corporation, Anika Therapeutics Inc., Bioventus LLC, Zimmer Biomet, Johnson & Johnson Services Inc., Aptissen S.A., Smith & Nephew Plc., Flexion Therapeutics Inc., Regen Lab SA, OrthogenRx Inc., Fidia Farmaceutici S.p.A, Ferring Pharmaceuticals, Laboratoires VIVACY, Allergan, Hyalgan, Synvisc, Euflexxa, Sanofi S.A., Wellchem Pharmaceuticals Pte Ltd., SingHealth Group.
North America was the largest region in the viscosupplementation market in 2024. The regions covered in the viscosupplementation market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the viscosupplementation market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Viscosupplementation involves the injection of hyaluronic acid gel directly into the joint to alleviate friction during movement. Hyaluronic acid, naturally present in synovial fluid surrounding joints, aids in reducing friction during joint motion.
The primary types of viscosupplementation include single-injection, three-injection, and five-injection methods. Single-injection viscosupplementation entails a direct injection of hyaluronic acid into the knee's diarthrodial joints, restoring the synovial fluid's rheological properties to generate anti-inflammatory and analgesic effects. Hyaluronic acid variations such as standard and stabilized forms, sourced from avian and non-avian origins, are used to address various osteoarthritic conditions such as knee, hip, and hand osteoarthritis. These treatments are administered across diverse healthcare settings, including hospitals, ambulatory surgical centers, among others.
The viscosupplementation market research report is one of a series of new reports that provides viscosupplementation market statistics, including viscosupplementation industry global market size, regional shares, competitors with a viscosupplementation market share, detailed viscosupplementation market segments, market trends, and opportunities, and any further data you may need to thrive in the viscosupplementation industry. This viscosupplementation market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The viscosupplementation market consists of revenues earned by entities by providing viscosupplementation therapy services such as plasma-rich platelet (PRP) injections and stem cell injections that are used in osteoarthritis (OA) treatment procedures. The market value includes the value of related goods sold by the service provider or included within the service offering. The viscosupplementation market also includes sales of hyaluronans and hylan injection preparations to provide viscosupplementation therapy services. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The viscosupplementation market size is expected to see rapid growth in the next few years. It will grow to $6.81 billion in 2029 at a compound annual growth rate (CAGR) of 10.6%. The growth in the forecast period can be attributed to regulatory support, alternative payment models, increased healthcare expenditure, research and development, expansion of indications. Major trends in the forecast period include outcome-based payment models, patient education initiatives, biomarker development, gene therapy research, value-based care models.
The increasing prevalence of osteoarthritis is poised to be a significant driver for the viscosupplementation market in the foreseeable future. Osteoarthritis, a degenerative joint disease and a common form of arthritis, manifests in the breakdown of joints, particularly in areas such as the hips, knees, and hands. Viscosupplementation treatment, involving the direct injection of hyaluronic acid into bone joints, serves to alleviate pain and enhance smooth bone movement. According to the Centers for Disease Control and Prevention (CDC), an American public health service organization, a projected 78.4 million adults aged 18 years and older in the USA are expected to be afflicted by arthritis by the year 2040. This underscores the pivotal role of the rising prevalence of osteoarthritis in propelling the growth trajectory of the viscosupplementation market.
Anticipated growth in healthcare expenditure is set to foster the expansion of the viscosupplementation market in the coming years. Healthcare expenditure, denoting the total spending on healthcare costs, encompasses the financial outlay on healthcare-related goods and services within a specific healthcare system or economy. The surge in healthcare expenditure plays a pivotal role in advancing the broader adoption and increased accessibility of viscosupplementation. This support extends to various aspects, including research, training, infrastructure development, and coverage by healthcare plans, ultimately benefiting individuals grappling with joint-related issues. As of November 2022, the Canadian Institute for Health Information, a U.S.-based not-for-profit organization, reported a notable increase in healthcare expenditure to 0.8%, reaching $331 billion in 2022, compared to 7.6% in 2021. Consequently, the upward trajectory of healthcare expenditure emerges as a driving force behind the growth of the viscosupplementation market.
The viscosupplementation market is witnessing a surge in popularity driven by advancements in technology. Companies within this market are strategically embracing new technologies to maintain their competitive edge. In August 2021, Seikagaku Corporation, a prominent Japanese pharmaceutical firm, unveiled HyLink, an innovative viscosupplement designed for intra-articular single injection to address knee osteoarthritis. HyLink incorporates cross-linking technology, a method used to create a long-lasting cross-linked hyaluronate hydrogel that effectively persists in the joint cavity, establishing it as a durable treatment solution. This move reflects Seikagaku Corporation's commitment to staying at the forefront of technological developments within the viscosupplementation sector.
Leading companies in the viscosupplementation market are actively pursuing innovation to secure a competitive advantage. A notable example is Nuvo Pharmaceuticals Inc., a Canada-based pharmaceutical company, which, in January 2021, introduced NeoVisc+ 2 mL and NeoVisc ONE 4 mL in the Canadian market. These products are hyaluronic acid (HA) viscosupplements specifically designed to address pain relief and enhance joint functionality in patients with degenerative or mechanical arthropathy of the knee, commonly associated with osteoarthritis. The launch of NeoVisc+ 2 mL and NeoVisc ONE 4 mL underscores Nuvo Pharmaceuticals Inc.'s dedication to delivering cutting-edge treatment options for knee pain and osteoarthritis, contributing to the overall growth of the viscosupplementation market in Canada.
In December 2021, Avanos Medical Inc., a medical technology company based in the United States, successfully completed the acquisition of OrthogenRx Inc. for a total transaction value of $160 million. This strategic move significantly expanded, diversified, and enhanced Avanos Medical Inc.'s chronic pain product portfolio, specifically by incorporating treatment options for individuals with knee osteoarthritis. The acquisition was strategically aligned with the company's objective to fortify its partnerships with healthcare providers on a global scale, particularly in the realm of musculoskeletal pain treatment. OrthogenRx Inc., a U.S.-based medical device company with expertise in viscosupplementation therapies for knee osteoarthritis, played a pivotal role in reinforcing Avanos Medical Inc.'s position in this therapeutic space.
Major companies operating in the viscosupplementation market include Seikagaku Corporation, Anika Therapeutics Inc., Bioventus LLC, Zimmer Biomet, Johnson & Johnson Services Inc., Aptissen S.A., Smith & Nephew Plc., Flexion Therapeutics Inc., Regen Lab SA, OrthogenRx Inc., Fidia Farmaceutici S.p.A, Ferring Pharmaceuticals, Laboratoires VIVACY, Allergan, Hyalgan, Synvisc, Euflexxa, Sanofi S.A., Wellchem Pharmaceuticals Pte Ltd., SingHealth Group.
North America was the largest region in the viscosupplementation market in 2024. The regions covered in the viscosupplementation market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the viscosupplementation market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Viscosupplementation involves the injection of hyaluronic acid gel directly into the joint to alleviate friction during movement. Hyaluronic acid, naturally present in synovial fluid surrounding joints, aids in reducing friction during joint motion.
The primary types of viscosupplementation include single-injection, three-injection, and five-injection methods. Single-injection viscosupplementation entails a direct injection of hyaluronic acid into the knee's diarthrodial joints, restoring the synovial fluid's rheological properties to generate anti-inflammatory and analgesic effects. Hyaluronic acid variations such as standard and stabilized forms, sourced from avian and non-avian origins, are used to address various osteoarthritic conditions such as knee, hip, and hand osteoarthritis. These treatments are administered across diverse healthcare settings, including hospitals, ambulatory surgical centers, among others.
The viscosupplementation market research report is one of a series of new reports that provides viscosupplementation market statistics, including viscosupplementation industry global market size, regional shares, competitors with a viscosupplementation market share, detailed viscosupplementation market segments, market trends, and opportunities, and any further data you may need to thrive in the viscosupplementation industry. This viscosupplementation market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The viscosupplementation market consists of revenues earned by entities by providing viscosupplementation therapy services such as plasma-rich platelet (PRP) injections and stem cell injections that are used in osteoarthritis (OA) treatment procedures. The market value includes the value of related goods sold by the service provider or included within the service offering. The viscosupplementation market also includes sales of hyaluronans and hylan injection preparations to provide viscosupplementation therapy services. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Viscosupplementation Market Characteristics3. Viscosupplementation Market Trends and Strategies4. Viscosupplementation Market - Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, and the Recovery from COVID-19 on the Market32. Global Viscosupplementation Market Competitive Benchmarking and Dashboard33. Key Mergers and Acquisitions in the Viscosupplementation Market34. Recent Developments in the Viscosupplementation Market
5. Global Viscosupplementation Growth Analysis and Strategic Analysis Framework
6. Viscosupplementation Market Segmentation
7. Viscosupplementation Market Regional and Country Analysis
8. Asia-Pacific Viscosupplementation Market
9. China Viscosupplementation Market
10. India Viscosupplementation Market
11. Japan Viscosupplementation Market
12. Australia Viscosupplementation Market
13. Indonesia Viscosupplementation Market
14. South Korea Viscosupplementation Market
15. Western Europe Viscosupplementation Market
16. UK Viscosupplementation Market
17. Germany Viscosupplementation Market
18. France Viscosupplementation Market
19. Italy Viscosupplementation Market
20. Spain Viscosupplementation Market
21. Eastern Europe Viscosupplementation Market
22. Russia Viscosupplementation Market
23. North America Viscosupplementation Market
24. USA Viscosupplementation Market
25. Canada Viscosupplementation Market
26. South America Viscosupplementation Market
27. Brazil Viscosupplementation Market
28. Middle East Viscosupplementation Market
29. Africa Viscosupplementation Market
30. Viscosupplementation Market Competitive Landscape and Company Profiles
31. Viscosupplementation Market Other Major and Innovative Companies
35. Viscosupplementation Market High Potential Countries, Segments and Strategies
36. Appendix
Executive Summary
Viscosupplementation Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on viscosupplementation market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for viscosupplementation ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The viscosupplementation market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- the market characteristics section of the report defines and explains the market.
- the market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- the forecasts are made after considering the major factors currently impacting the market. These include:
- the forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- the regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- the competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- the trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) by Type: Single Injection Viscosupplementation; Three Injection Viscosupplementation; Five Injection Viscosupplementation2) by Source: Avian Origin; Non-Avian Origin
3) by Hyaluronic Acids: Standard Hyaluronic Acid; Stabilized Hyaluronic Acid
4) by Application: Knee Osteoarthritis; Hip Osteoarthritis; Hand Osteoarthritis
5) by End-User: Hospitals; Ambulatory Surgical Centers; Other End-Users
Subsegments:
1) by Single Injection Viscosupplementation: Hyaluronic Acid-Based Products; Non-Hyaluronic Acid Products2) by Three Injection Viscosupplementation: Hyaluronic Acid-Based Products; Combination Products
3) by Five Injection Viscosupplementation: Hyaluronic Acid-Based Products; Combination Products
Key Companies Mentioned: Seikagaku Corporation; Anika Therapeutics Inc.; Bioventus LLC; Zimmer Biomet; Johnson & Johnson Services Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
Some of the major companies featured in this Viscosupplementation market report include:- Seikagaku Corporation
- Anika Therapeutics Inc.
- Bioventus LLC
- Zimmer Biomet
- Johnson & Johnson Services Inc.
- Aptissen S.A.
- Smith & Nephew Plc.
- Flexion Therapeutics Inc.
- Regen Lab SA
- OrthogenRx Inc.
- Fidia Farmaceutici S.P.A
- Ferring Pharmaceuticals
- Laboratoires VIVACY
- Allergan
- Hyalgan
- Synvisc
- Euflexxa
- Sanofi S.A.
- Wellchem Pharmaceuticals Pte Ltd.
- SingHealth Group
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | February 2025 |
| Forecast Period | 2025 - 2029 |
| Estimated Market Value ( USD | $ 4.55 Billion |
| Forecasted Market Value ( USD | $ 6.81 Billion |
| Compound Annual Growth Rate | 10.6% |
| Regions Covered | Global |
| No. of Companies Mentioned | 21 |
